ExCellThera announces new publication showing its ECT-001 cell therapy improves transplant access for all patients
13 avr. 2022 08h05 HE
|
ExCellThera
MONTREAL, April 13, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer...
ExCellThera announces new data to be presented at the EBMT 2022 annual meeting
15 mars 2022 08h04 HE
|
ExCellThera
MONTRÉAL, March 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand...
ExCellThera announces first patient treated in Phase I/II trial of ECT-001 cell therapy for pediatric patients with high risk blood cancer
10 mars 2022 08h04 HE
|
ExCellThera
MONTREAL, March 10, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and...
ExCellThera announces settlement of its patent infringement claims against Selleck Chemicals
21 déc. 2021 08h05 HE
|
ExCellThera
MONTRÉAL, Dec. 21, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer...
ExCellThera announces data to be presented at the American Society of Hematology 2021 annual meeting
29 nov. 2021 08h05 HE
|
ExCellThera
MONTRÉAL, Nov. 29, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer...
ExCellThera and Astellas enter into a license for the use of molecule UM171 in the field of pluripotent stem cells
13 juil. 2021 08h05 HE
|
ExCellThera
MONTREAL, July 13, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune...
Excellthera and Ossium Health Announce a Collaboration to Advance Their Technologies and Platforms to Improve Human Health
21 avr. 2021 08h02 HE
|
ExCellThera
MONTREAL, April 21, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells...
ExCellThera announces UM171 mechanism of action
07 janv. 2021 11h15 HE
|
ExCellThera
MONTRÉAL, Jan. 07, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera receives Priority Medicines (PRIME) designation from European Medicines Agency for ECT-001 Cell Therapy
11 déc. 2020 07h55 HE
|
ExCellThera
MONTREAL, Dec. 11, 2020 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera announces publication in The Lancet Haematology highlighting excellent clinical results of ECT-001 in patients with haematological malignancies
06 nov. 2019 07h00 HE
|
ExCellThera
MONTREAL, Nov. 06, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use,...